Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma.
10.3779/j.issn.1009-3419.2018.12.07
- Author:
Lei LIU
1
;
Ruochuan ZANG
1
;
Peng SONG
1
;
Shugeng GAO
1
Author Information
1. Department of Thoracic Surgery, Nationanl Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Scienses and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Lung neoplasms;
Prognosis;
Pulmonary sarcomatoid carcinoma;
Treatment
- MeSH:
Carcinoma, Non-Small-Cell Lung;
diagnosis;
therapy;
Lung Neoplasms;
diagnosis;
therapy;
Prognosis
- From:
Chinese Journal of Lung Cancer
2018;21(12):902-906
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary sarcomatoid carcinoma (PSC) is a rare, poorly differentiated, subtype of non-small cell lung carcinoma (NSCLC) and constitutes approximately 0.1% to 0.5% of all lung malignancies. PSC can be divided into five subtypes based on the 2015 World Health Organization (WHO) classification of lung tumors: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. Some imaging characteristics can be found for PSC although no special symptoms. The accurate pathological diagnosis of PSC can be a significant challenge, which depends on pathology and immunohistochemistry. PSC should be managed similar to other NSCLC, surgical resection is the standard management for early stage cases, moreover, multimodal treatment should be considered. However, PSC is insensitive to radiotherapy and chemotherapy, and has high rate of local and metastatic recurrence and poor prognosis. With the development of molecular pathology, targeted therapy and immunotherapy may have broad prospects.
.
